Scynexis Inc (SCYX) - News Archive

In a significant stride towards combating the challenge posed by invasive fungal infections, SCYNEXIS, Inc. (NASDAQ: SCYX) has initiated dosing in its Phase 1 clinical trial of SCY-247, a second-generation triterpenoid...

In a significant stride towards addressing the ever-growing challenge of difficult-to-treat and drug-resistant infections, SCYNEXIS, Inc. (NASDAQ: SCYX) has announced that it will present groundbreaking preclinical data...

Interpreting the Facts: Despite a Net Increase in Borrowings, Scynexis Inc Enhances Tangible Leverage RatioIn the third quarter of 2023, Scynexis Inc saw a net increase in borrowings of -8.45%, yet managed to enhance it...

SCYNEXIS, Inc., a leading biotechnology company focused on developing breakthrough treatments for challenging and drug-resistant infections, recently unveiled groundbreaking preclinical efficacy data for its second gene...

SCYNEXIS Presents Promising Preclinical Data on Second Generation Fungerp SCY-247 against MucormycosisJERSEY CITY, N.J., Jan. 29, 2024 - SCYNEXIS, Inc. (NASDAQ: SCYX), a pioneering biotechnology company specializing in...